Pacific Biosciences of California Inc (NASDAQ:PACB) currently has a daily average trading volume of 9.80M but it saw 15865208 shares traded in last market. With a market cap of 438.18M USD, the company’s current market price of $1.60 came falling about -8.31 while comparing to the previous closing price of $1.75. In past 52 weeks, the stock remained buoying in the range of price level as high as $7.50 and as low as $1.16. In the recent trading on the day, stock has struck highest price mark of $1.59 while lowest mark touched by it was $1.75.
Taking a look at 20-day trading activity of Pacific Biosciences of California Inc (PACB) gives us an average price of $1.9097, while its current price level is -78.67% below from 52-week high level whereas it is 37.93% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.9863 while that of 200 days or SMA-200 reads an average of $1.8638. A closer look into the stock’s movement over the week reveals that its volatility is standing at 11.91% during that period while stretching the period over a month that decreases to 9.19%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 35.46 which implies that the stock is in neutral territory.
Over the week, PACB’s stock price is moving -23.81% down while it is -18.37% when we observe its performance for the past one month. Year-to-date it is -12.57% down and over the past year, the stock is showing a downside performance of -75.08%.
The company is expected to be releasing its next quarterly report in February, for which analysts forecasted an EPS of -0.18 while estimate for next year EPS is -0.81. In next quarter, company is expected to be making quarterly sales of $42.31M as analysts are expecting the sales for current fiscal year at $155.39M and seeing the company making $187.81M in sales next year. Moreover, analysts are in estimates of $40.68M for current-quarter revenue.
Currently, Pacific Biosciences of California Inc’s total number of outstanding shares is 273.81M with 9.31% of that held by the insiders while 84.56% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -28.92% and return on equity (ROE) at -64.80%. Stock’s beta reads 1.94. Stock has a price to book (P/B) ratio of 0.97 while price to sale or P/S ratio amounts to 2.53. Its return on asset (ROA) is -23.55% on average.
